Aurinia Pharmaceuticals

AUPH

Market cap $2.13B

Here is how Aurinia Pharmaceuticals (AUPH) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Aurinia Pharmaceuticals (AUPH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Aurinia Pharmaceuticals Inc. ( AUPH ) Q3 2025 Earnings Call November 4, 2025 8:30 AM EST Company Participants Peter Greenleaf - President, CEO & Director Joseph Miller - Chief Financial Officer Greg Keenan - Chief Medical Officer Conference Call Participants Stacy Ku - TD Cowen, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Maurice Raycroft - Jefferies LLC, Research Division Will Soghikian - Leerink Partners LLC, Research Division Yu He - H.C. Wainwright & Co, LLC, Research Division David Martin - Bloom Burton & Co., Research Division Douglas Miehm - RBC Capital Markets, Research Division Presentation Operator Good morning.

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.1 per share a year ago.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and nine months ended September 30, 2025, and provided an update on recent business progress. Financial Results Total Revenue: For the three and nine months ended September 30, 2025, total revenue was $73.5 million and $205.9 million, up 8% and 17%, respectively, from $67.8 million and $175.3 million, respectively, for the same periods of 2024. Net Pro.

Aurinia Pharmaceuticals (AUPH) files a federal lawsuit against FDA's George Tidmarsh for alleged false statements about its lupus nephritis drug. Baidu's (BIDU) Apollo Go robotaxi service matches Waymo's weekly ride volume, while Pony AI (PONY) prepares for a major Hong Kong IPO.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for the three and nine months ended September 30, 2025, and provide an update on recent business progress on November 4, 2025. Aurinia's management team will host a webcast and conference call on November 4, 2025, at 8:30 a.m. ET. The link to the webcast is available here. To join the conference call, please dial 877-407-9170 / +1 201-493-6756. A.

Aurinia Pharmaceuticals is rated BUY, driven by strong Lupkynis sales growth and a robust cash position supporting pipeline development. AUPH's Lupkynis leads as the first FDA-approved oral therapy for lupus nephritis, with 22% YoY revenue growth and expanding physician adoption. The company's pipeline drug, AUR200, targets dual immune proteins and offers long-term diversification potential in a multi-billion-dollar autoimmune market.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at ACR Convergence and ASN Kidney Week 2025.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Responds to Now Retracted LinkedIn Post.